Early Treatment of Acute Pancreatitis with Rectal Indomethacin in Adults Aged 18 to 80 A Multi-center, Double-blind, Placebo-controlled Phase 4 Trial
Led by Peking Union Medical College Hospital · Updated on 2025-06-15
1504
Participants Needed
17
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of indomethacin, a non-steroidal anti-inflammatory drug NSAID, as an early treatment for acute pancreatitis AP, a condition where the pancreas becomes inflamed due to enzyme activation. The study aims to clarify the effects of NSAIDs on AP treatment, as previous animal studies suggested potential benefits but clinical evidence has been inconsistent. This Phase 4, multi-center, double-blinded, placebo-controlled trial seeks to provide high-quality data on this topic.
Participants will be randomly assigned to receive either indomethacin SR 50 mg suppositories every 12 hours from admission day 1 to day 7 alongside standard AP treatments or similar placebo suppositories on the same schedule with standard care. Standard treatment includes adequate intravenous fluids, pain relief, and early enteral nutrition if possible. The study compares these two groups to assess the impact of indomethacin on AP outcomes.
During the study, participants will be monitored for organ dysfunction related to AP over one week, which is the primary outcome. Secondary outcomes include rates of pancreatic necrosis, ICU admission, and mortality within one month. Assessments will involve clinical evaluations and imaging. The study runs from admission through at least one month, with close safety monitoring and follow-up to understand treatment effects and patient health outcomes over time.
CONDITIONS
Brief Title
Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)
Research Team
D
Dong Wu, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with acute pancreatitis based on at least two of the following: characteristic abdominal pain, serum amylase or lipase at least 3 times the upper normal limit, or characteristic findings on abdominal CT scan
You will not qualify if you...
Symptom onset more than 24 hours before screening
Renal dysfunction with serum creatinine above 1.5 times normal upper limit
Severe liver dysfunction
Active peptic ulcer disease or gastrointestinal bleeding
Pregnancy or breastfeeding
Hypersensitivity to NSAIDs
New-onset, worsening, or uncontrolled hypertension
Serious cardiovascular events such as severe heart failure, myocardial infarction, or stroke
Mental disability
Malignancy-associated acute pancreatitis
Post-ERCP pancreatitis
Not having signed informed consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 7 days
Participants receive rectal Indomethacin or placebo suppositories every 12 hours from admission day 1 to day 7, along with standard care for acute pancreatitis including intravenous fluids, pain management, and nutrition support if possible.
Daily visits during treatment period
Follow-up
Duration - Up to 1 month
Participants are monitored for outcomes such as organ dysfunction, pancreatic necrosis, ICU admission, and mortality.
1 to 2 visits within 1 month after treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating a Single Dose of RABI-767 by Endoscopic Ultrasound Injection Compared to Standard Care in Adults with Predicted Severe Acute Pancreatitis
Comparing Womens Sexual Quality of Life After Benign Adnexal Surgery Using vNOTES or Conventional Laparoscopy
Observational Study Collecting Medical Information and Tissue Samples
From Patients With Pancreatic Cancer or Other Pancreatic Diseases to Support Research
Study Comparing Safety and Effectiveness of Laparoscopic Surgery for Gastrointestinal Stromal Tumors in Different Tumor Locations
Studying Complications of Alveolar Opening Maneuvers and PEEP in Children on Mechanical Ventilation with Respiratory Distress Syndrome
Blood Biomarker Study for Detecting Infected Pancreatic Necrosis in Adults with Necrotizing Pancreatitis
Study of Diabetes Development After Acute Pancreatitis and Its Underlying Mechanisms Over 3 Years
Using Continuous Glucose Monitoring to Understand Diabetes Risk and Treatment After Acute Pancreatitis
An Observational Study by the Type 1 Diabetes in Acute Pancreatitis Consortium
Electronic Archive Study on Severe Liver Disease and Liver Transplantation with 10-Year Data Collection
Randomized Double-Blind Study of Gut Microbiota Transplantation for Moderate to Severe Acute Pancreatitis Treatment
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The effect of lornoxicam on TLR2 and TLR4 messenger RNA expression and tumor necrosis factor-α, interleukin-6, and interleukin-8 secretion in patients with systemic complications of acute pancreatitis.
Victor Aleksandrovitch Gorsky, Mikhail Adnreevitch Agapov, Marina Victorovna Khoreva...